Stephanie Lee, MD, MPH - Overcoming GVHD Is the Key to Better HCT Outcomes: Guidance on Managing Acute and Chronic Disease

Go online to PeerView.com/CJR860 to view the activity, download
slides and practice aids, and complete the post-test to earn
credit. Preventing and managing graft-versus-host disease (GVHD)
remains a significant problem in the post–allogeneic hematopoietic
stem cell transplant (HCT) setting. Can a wide range of unique
treatment modalities, including costimulatory compounds, targeted
agents, and engineered cell therapy, challenge long-standing
management protocols in this setting? Find out in this activity,
based on a recent live symposium, which features an overview of
available and emerging therapeutic options for modern GVHD
management as a means to extend the benefits of HCT and provide
more effective prophylaxis and treatment. Upon completion of this
activity, participants should be better able to: Summarize current
safety/efficacy evidence supporting the use of novel therapeutics
for prophylaxis or treatment of acute or chronic
graft-versus-host-disease (GVHD) in the post-transplant setting;
Develop management plans with novel and emerging therapeutics for
the prophylaxis of GVHD in the post-transplant setting, based on
current evidence and practice guidelines; and Integrate novel and
emerging therapies into safe, personalized treatment plans for the
management of acute or chronic GVHD, including novel combinatorial
strategies and/or options for second-line management.